Journal of Cancer Research and Therapeutics

REVIEW ARTICLE
Year
: 2016  |  Volume : 12  |  Issue : 7  |  Page : 131--137

Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer


Kaixian Zhang, Qianqian Yuan 
 Department of Oncology, Tengzhou Central People's Hospital, Tengzhou, Shangdong, P.R. China

Correspondence Address:
Kaixian Zhang
Department of Oncology, Tengzhou Central People's Hospital, Xingtan Road No. 181, Tengzhou 277599, Shangdong
P.R. China

Abstract

Lung cancer continues to be a major health problem and the most common cancer-related mortality worldwide with about 80%–85% patients suffering from nonsmall cell lung cancer (NSCLC). More than 80% of NSCLC cases are often diagnosed as advanced stage and harbor epidermal growth factor receptor (EGFR) activating mutation. Although great success in initial response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) are found in EGFR-mutant NSCLC patients, acquired resistance usually occurs on the continuous treatment. Here, we provide an overview on the mechanism of acquired resistance to EGFR-TKIs in NSCLC therapy as well as current preclinical and clinical evidence of new therapy strategies and inhibitors in the treatment of NSCLC. Many studies have shown that original or induced T790M mutation, human EGFR 2 amplification, and activated secondary signaling such as MET amplification or phosphatidylinositol 3-kinase mutation can lead to acquired resistance to EGFR-TKIs. In addition, transformation from NSCLC to SCLC or conferred epithelial to mesenchymal transition has also been identified as mechanisms of acquired resistance to EGFR-TKIs. Increasing evidence has proven that non-coding RNA including long noncoding RNAs and microRNAs or new EGFR mutation is involved in acquired resistance. Preclinical and clinical Phase 1–3 evidence on combination drug therapy or new generation inhibitors with different tumor-targeting approaches have made those strategies the promising options for EGFR-TKI-resistant NSCLC therapy. This review aims to get deep insight into providing a state-of-the-art overview of the recent advances in the mechanisms of acquired resistance and new strategies for targeted cancer therapy in EGFR-TKI-resistant NSCLC.



How to cite this article:
Zhang K, Yuan Q. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.J Can Res Ther 2016;12:131-137


How to cite this URL:
Zhang K, Yuan Q. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer. J Can Res Ther [serial online] 2016 [cited 2022 May 27 ];12:131-137
Available from: https://www.cancerjournal.net/text.asp?2016/12/7/131/200613


Full Text

 Introduction



Lung cancer ranked the first in males and top five in females of newly diagnosed cancer cases and the cancer-related deaths worldwide with a generally grim prognosis, with over 80% of the patients falling into the category of nonsmall cell lung cancer (NSCLC). NSCLC is often diagnosed as advanced stage, and the opportunity for surgical resection is lost. Chemotherapies with either mono application or combo-administration of platinum-based or other cytotoxic chemicals are usually traditional strategies for NSCLC treatment. However, the objective efficacy of these strategies was often unsatisfactory, with median overall survival usually <1 year.

In approximately 30% of the NSCLC patients whose tumors harbor epidermal growth factor receptor (EGFR) activating mutation, EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib show tremendous success in the past decades.[1],[2] However, despite an initial dramatic response to EGFR-TKIs, acquired resistance usually occurred when patients were treated with EGFR inhibitors for 10–14 months. Multiple mechanisms of acquired resistance to EGFR-TKIs have been identified, such as original or induced T790M hot spot mutation, human epidermal growth factor receptor 2 (HER2) amplification, activated secondary signaling such as MET amplification or phosphatidylinositol-3 kinase (PI3K) mutation, and conversion from NSCLC to SCLC or conferred epithelial to mesenchymal transition (EMT).[3],[4] Nevertheless, combined applications of EGFR-TKIs with chemotherapies brought about higher occurrence of adverse effects, rather than the expected benefit of extending the overall survival of the treated objects. Therefore, it is necessary to get deep insight into updated resistant mechanism for developing new strategies or agents to overcome EGFR-TKIs resistance and it is critical to prolong the survival of patients with NSCLC.

 Epidermal Growth Factor Receptor-T790m Mutation



EGFR inhibitors, such as erlotinib, gefitinib, and afatinib, exhibited high objective response rates and increased overall survival of NSCLC patients with oncogenic EGFR mutation (i.e., exon 19 deletions or exon 21 L858R single-point mutation).[2],[5] However, despite an initial dramatic response to TKIs, patients become resistant upon the continuous treatment. Lots of evidence indicate that more than half of the EGFR-TKI resistance is caused by a secondary T790M (Thr790 → MET) mutation in the catalytic cleft of the EGFR tyrosine kinase domain.[6],[7] Previous structural modeling analysis of the erlotinib-bound EGFR model showed that this threonine residue was critical for the binding of erlotinib to EGFR and methionine substitution caused steric hindrance, which interfered with drug-receptor binding.[8] Other evidence suggests that this modification disturbs the proper binding of the drug to the adenosine triphosphate (ATP) pocket of EGFR and to restore the affinity for ATP at the level of wild-type EGFR.[9],[10]

 Human Epidermal Growth Factor Receptor 2 Mutation and Amplification



HER2/neu (ErbB2), EGFR (ErbB1), HER3 (ErbB3), and HER4 (ErbB4) belong to the ErbB receptor tyrosine kinase (RTK) family, which present an attractive option for targeted therapy in patients with NSCLC according to the oncogenic mutation patterns of EGFR and HER2.[2],[11],[12] HER2 with an in-frame YVMA insertion at residue 776 is the most common abnormality detected in a survey of 96 unselected NSCLC specimens.[13] Cancer cells expressing HER2YVMA exhibited resistance to the EGFR-TKIs such as erlotinib and gefitinib, but they remained sensitive to direct HER2 inhibitors.[12] Highly expressed EGFR and/or HER2 have been associated with poor prognosis. Increased EGFR or HER2 gene copy numbers had a tendency to be associated with short survival in NSCLC.[14],[15] Through the study of preclinical in vitro and in vivo models as well as human tissues, researchers have identified that HER2 overexpression confers resistance to EGFR-TKIs in cell line models, and HER2 is amplified in both murine and human tumors with acquired resistance to erlotinib. Findings of those researchers indicate that HER2 amplification serves as a new mechanism of acquired resistance to EGFR-TKIs in EGFR-mutant NSCLC tumors, occurring independently of the EGFR T790M secondary mutation.[4]

 MET Amplification



As a hepatocyte growth factor (HGF) receptor, MET is a RTK. Lots of evidence point to MET as a key oncogenic driver in several human cancers including small cell (SCLC) and NSCLC.[16] Another report nominated amplifications in MET as one of the driver events specifically in otherwise oncogene-negative lung adenocarcinomas.[17] Activation of MET-HGF pathway has been reported as one of the most critical events responsible for acquired anti-EGFR therapy resistance, and patients with increased MET gene copy numbers showed poor prognosis and resistance to EGFR-TKIs.[18],[19],[20] It has been reported that MET amplification results in gefitinib resistance in lung cancer by activating ErbB3 signaling.[20] Some data showed that about 20% of patients with acquired resistance to EGFR inhibition therapy harbor MET amplification.[21] A previous report showed that MET amplification is one potential mechanism of resistance to third-generation EGFR-TKIs identified by FISH.[22] The MET amplification accounts for approximately 5% of mechanism of resistance to first-generation EGFR-TKIs.[23] Recent report shows that high-level MET amplification is identified as a resistance mechanism to osimertinib (AZD9291) which parallels mechanisms of acquired resistance to first-generation EGFR-TKIs.[24] Another report also confirms that MET amplification and protein hyperactivation is a resistance mechanism to both first- and third-generation EGFR-TKIs, suggesting that MET inhibition is a possible strategy to overcome resistance of certain EGFR-mutated NSCLCs with MET amplification to AZD9291.[25]

 PIK3CA Mutation



The ErbB family members are transmembrane RTKs, and their network activation leads to receptor autophosphorylation in C-terminal tyrosine and the recruitment to these sites of cytoplasmic signal transducers which include PLC-γ1, Ras/Raf/MEK/MAPKs, PI3K/Akt/ribosomal S6 kinase, Src, stress-activated protein kinases, PAK/JNKK/JNK, and the signal transducers and activators of transcription. PI3K pathway oncogenic activation can occur in several ways as follows: (1) mutation or amplification of gene encoding including RTKs (EGFR and HER2), subunits of PI3K (p110alfa, p110beta, p85alfa, and p85beta) and Akt; (2) activating isoform of Ras; (3) mutations, deletions, loss of functions, or epigenetic silencing of PTEN. PI3K mutations were found in about 4% of squamous cell carcinoma and 2.7% of adenocarcinoma. PI3K mutation can coexist with EGFR mutation or KRAS mutation in adenocarcinoma lung cancer.[26] Some previous data show that in a gefitinib-resistant NSCLC cell line, continued activation of PI3K signaling by the PIK3CA oncogenic mutant, p110alpha E545K, was sufficient to abrogate gefitinib-induced apoptosis.[27] Another group observed 5% patients with acquired PIK3CA mutations in EGFR-TKI-resistant NSCLC patients with mutant EGFR.[28] A study in vitro identified that loss of PTEN involved in resistance to EGFR-TKIs.[29] Some investigations confirm that PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer through activating Akt and EGFR.[30] Some PI3K inhibitors are in progress, and several recently completed trials were leaded with PI3K inhibitor as single agent or in association with chemotherapy or other agents.

 Epidermal Growth Factor Receptor Exon 18–25 Kinase Domain Duplication



Mutations occurring as either small in-frame deletions in exon 19 or point mutations in exon 21 (L858R) usually confer sensitivity to EGFR-TKIs.[31] ALK and ROS1 gene rearrangements have similarly allowed for the rational treatment for NSCLC. However, despite these significant advances in defining clinically relevant molecular cohorts of lung cancer, the currently identified genomic alterations account for only 50%–60% of all tumors. Recently, one targeted next-generation sequencing-based genomic profiling has first demonstrated a novel in-frame tandem duplication of EGFR exons 18–25 kinase domain duplication (EGFR-KDD).[32] Although the index patient treated with the EGFR inhibitor afatinib experienced marked improvement and significantly decreased-tumor burden, the patient's tumor harbored an increase in the copy number of the EGFR-KDD upon disease progression. For the first time, EGFR-KDD is identified as an oncogenic and therapeutically actionable alteration through analysis of a large set of annotated lung, brain, and soft-tissue tumors and cancer cell models.

 Noncoding RNA



Long noncoding RNAs (lncRNAs) are transcripts of longer than 200 nucleotides with no protein coding function. Various studies have indicated that lncRNAs, including UCA1, HOTAIR, H19, CUDR, AK126698, and MALAT1, are associated with chemotherapy and/or EGFR-TKI resistance.[33],[34],[35],[36],[37] A report manifests that some lncRNAs, including lncRNA BC087858, are upregulated in gefitinib-resistant cells.[38] Further investigation shows that lncRNA BC087858 can induce acquired resistance to EGFR-TKIs by activating PI3K/Akt/ERK pathway and EMT in EGFR-mutant NSCLC.[39]

MicroRNAs (miRNAs) as a small noncoding RNAs family of 19–24 nucleotides are involved in a variety of biological processes by regulating the expression of target genes. miR-134, miR-487b, and miR-23a were found to promote gefitinib resistance.[40],[41] miR-21 is able to generate gefitinib resistance through activating ALK and ERK and suppressing PTEN in NSCLC.[42],[43] miR-30b and miR-30c induced by EGFR and MET promote gefitinib resistance through inhibiting Bim.[42] Similarly, miR-221 and miR-222 also increased by EGFR and MET enhance gefitinib resistance through inhibiting apoptotic peptidase activating factor-1.[42] miRNAs are able to involve in drug resistance in positive and negative manners. Inhibition of miRNAs that promote drug resistance and enhancement of miRNAs that reverse drug resistance may provide novel prospect for combined targeted treatments in NSCLC.

 Epithelial to Mesenchymal Transition



EMT signifies reversion of epithelial phenotype and acquisition of mesenchymal characteristics, accompanied with a biological progression consisting of reversible events. Previous study shows that EMT is a determinant of sensitivity of NSCLC cell lines and xenografts to EGFR-TKIs.[44] Another investigation demonstrates that EMT markers are increased in patients with NSCLC showing resistance to cisplatin-based chemoradiotherapy.[45] EMT induction in vitro makes NSCLC cells with EGFR mutations less sensitive to EGFR-TKIs.[46],[47],[48] Recent evidence shows that EMT can contribute to drug resistance in several carcinomas such as pancreatic cancer and lung cancer.[49],[50] The acquisition or reversion of EMT was consistent with the changes in drug sensitivity. EGFR-mutant NSCLC cells exhibit a decreased sensitivity to gefitinib when an EMT phenotype is induced by transforming growth factor (TGF), HGF, or interleukin 6.[51],[52],[53] Sensitivity to cisplatin is decreased in NSCLC cells for EMT induction by TGF, and sensitivity to etoposide is less in SCLC cells with an HGF-induced EMT.[54],[55] New therapeutic strategies of reverting EMT might be used for overcoming resistance to chemotherapy and/or targeted therapy.

 Conversion of Nonsmall Cell Lung Cancer to Small Cell Lung Cancer



Some studies showed that after an initial response to EGFR-TKIs, EGFR-mutated adenocarcinoma is transformed to SCLC and a similar activating mutation is confirmed by EGFR mutation analysis in both original lung adenocarcinoma and metastatic SCLC of these patients.[56],[57] Other case describes that EGFR-mutant metastatic adenocarcinoma is transformed into SCLC after developing resistance in a never-smoking female.[58] An investigation manifests that after developing clinical resistance to EGFR-TKI, a pretreatment adenocarcinoma is transformed into a combined SCLC-adenocarcinoma in one patient and four patients have EGFR-mutant SCLC or mixed histology tumors.[59] The finding that the same EGFR-mutant cancer can manifest both as an adenocarcinoma and as a SCLC hints at the existence of a pluripotent population of EGFR-mutant cancer cells or cancer stem cells that are the source of resistance.[28] SCLC histology has been found in 3%–14% of patients with acquired resistance to EGFR-TKIs.[23] A high frequency of conversion of NSCLC to SCLC, together with marked EGFR amplification, PIK3CA mutations, EMT, and the loss of genetic resistance mechanisms are observed in the absence of continuous TKI treatment.

 Prospective Strategies or Agents to Overcome Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer



Although EGFR inhibitors for NSCLC treatment have been applied in clinical practices with great success, their clinical benefits were somewhat hampered by the rising acquired resistance. New generation inhibitors or combination drug therapy could be effective strategies to cope with the challenge.

New generation inhibitors

Acquired resistances after treatment with first-generation EGFR-TKIs lead researchers to develop second-generation EGFR-TKIs, in which afatinib has progressed furthest in clinical development and has been approved by NICE as an option for first-line EGFR-TKI therapy. Dacomitinib and three other compounds including pelitinib, canertinib, and ceratinib were investigated but are no longer in development for patients with NSCLC for disappointing clinical results.[60]

Third-generation inhibitors are in development, of which AZD9291 and rociletinib have the furthest progression in clinic. To solve resistance caused by T790M mutation, new inhibitors with irreversible binding to the ATP pocket of EGFR and the selective targeting of T790M-harboring receptors have been developed.[61],[62],[63] A mono-anilino-pyrimidine compound AZD9291, as a novel and irreversible EGFR-TKI, has proved to be more effective against both EGFR-TKI sensitizing and resistant T790M mutation in preclinical models and Phase 1 clinical study.[64] Although new irreversible inhibitors are more potent than gefitinib against T790M, more studies are needed for the efficacy and safety of these new generation EGFR-TKIs in the Phase 3 clinical trials.[65] Rociletinib is a potent irreversible inhibitor of sensitizing EGFR mutations and T790M-resistant mutations. Rociletinib is in Phase 2 and 3 studies. For HM61713, an irreversible mutant-selective EGFR inhibitor that is wild-type sparing, an expansion cohort at increased dose is planned.[66]

As one of the third-generation irreversible EGFR-TKIs, osimertinib can specifically target common activating EGFR mutations − exon19 deletion and L858R and the T790M resistance mutation.[61] The mutation at the cysteine (C797) residue that osimertinib binds to lead to its resistance.[67],[68] For the current available first- and second-generation EGFR-TKIs can inhibit this C797S mutation in vitro, a combination of first- and third-generation EGFR-TKIs has been proposed as a therapeutic strategy to overcome the C797S/T790M mutations if the mutations occur in separate allele of the chromosome.[68]

Combination of epidermal growth factor receptor with MET blockade

Several combination strategies are being investigated, but results are preliminary and immature. One of the strategies is combination of MET inhibitors such as MET inhibitors, such as cabozantinib, tivantinib, and INC280. Although many new MET inhibition compounds including antibody inhibition, small-molecule inhibitors, and others have entered clinical trials, the frequency of MET amplification in NSCLC ranges from 3% to 10%, depending on the detection technique, cutoff criteria, and selection of samples.[69] Preclinical data demonstrated that combination of afatinib with cetuximab (EGFR-targeting antibody) resulted in tumor response in erlotinib-resistant tumor xenografts, and the combination efficacy will be investigated by a Phase 2/3 trial.[60],[70] Other combined inhibitor therapies including PI3K inhibitor (buparlisib), heat shock protein 90 inhibitor (AUY922), or JAK inhibitor (ruxolitinib) are in clinical development.

Combined targeting of epidermal growth factor receptor and pyruvate dehydrogenase kinase

Glycolysis, as a predominant process for most cancer cells to utilize glucose, is involved in cancer development. Targeting critical glycolysis enzymes, such as pyruvate dehydrogenase kinase (PDK), might be a promising approach to work alone or in combination with other treatments for cancer therapy. As a widely regarded PDK inhibitor, dichloroacetate (DCA) attenuates cancer progression in many cancers.[71] Previously, several combinations of DCA with platinum-based drug for NSCLC treatment have been reported and majority of them were focused on the classical cytotoxic chemotherapy.[72],[73] Recent report has showed that combination of erlotinib and gefitinib with DCA exerts synergistic effects in an EGFR-mutant NSCLC.[74]

Combination treatment of epidermal growth factor receptor-tyrosine kinase inhibitor and Bcl-2 inhibitors

Overexpression of anti-apoptotic Bcl-2 family members (i.e., Bcl-2, Bcl-XL, and Mcl-1) and dysregulation of proapoptotic family members (i.e., Bad, Bim, Bax, Bak, etc.) are involved in the mediation of chemo- or radio-resistance in human lung cancers, indicating that Bcl-2 family members have the potential to be critical targets for lung cancer treatment. An investigation revealed that Bcl-2 knockdown induced by small interfering could reverse acquired T790M mutation in EGFR-TKIs-resistant H1975 cell line.[75] The members of Bcl-2 family own four conserved Bcl-2 homology (BH) domains: BH1, BH2, BH3, and BH4.[76] The BH3 mimetic agents could bind to the hydrophobic cleft of Bcl-2/Bcl-XL to act as competitive inhibitors.[77],[78] Gossypol (AT-101), a pan-Bcl-2 inhibitor, has shown antitumor effect in several cancer cell lines.[79],[80],[81] Recent study has revealed that AT-101 enhances gefitinib sensitivity in NSCLC with EGFR T790M mutations and the combined treatment with AT-101 and gefitinib induced additional cell death in vitro and in vivo.[82] Although four Bcl-2 inhibitors, oblimersen sodium (G3139), gossypol (AT-101), obatoclax (GX15-070), and ABT-263, have already been tested in human clinical trials, they showed limited clinical efficacy.[77],[83] The BH4 domain is required for the survival activity of Bcl-2, and its removal can convert Bcl-2 from a survival to a killer molecule.[84] BDA-366, a small-molecule Bcl-2-BH4 domain antagonist, is recently identified and exhibits potent efficacy against human lung cancer.[85]

Immunotherapy

PD-1 pathway activation contributes to immune evasion in EGFR-driven lung cancers.[86] Phase 1 trials combining EGFR-TKIs with immunotherapies are ongoing, including several anti-PD-1 monoclonal antibody (nivolumab, pembrolizumab, and MPDL3280A).[60] Nivolumab, a fully human IgG4 immune checkpoint inhibitory antibody, could bind to PD-1, preventing its interaction with its ligands PD-L1 and PD-L2.[87],[88] In different cancer types, tumor infiltrating lymphocytes have been found to express PD-1, while the upregulation of PD-L1 by tumor cells has been interpreted as a possible mechanism of resistance of the tumor to the host immune response.[87],[89] Nivolumab has been approved in the US and Europe as second-line treatment for advanced NSCLC.[90]

An improved understanding of the mechanisms of acquired EGFR-TKI resistance and treatment strategies that are rationally tailored to them drives the treatment into a new exciting phase in NSCLC. These findings will provide a new concept for the development of novel therapeutic approaches in the treatment of refractory and relapsed patients who are no longer sensitive to EGFR-TKIs. In the future, the co-treatment strategy or new generation inhibitor in the clinical setting remains to be further clarified.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010;10:760-74.
2Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
3Maione P, Sacco PC, Sgambato A, Casaluce F, Rossi A, Gridelli C. Overcoming resistance to targeted therapies in NSCLC: Current approaches and clinical application. Ther Adv Med Oncol 2015;7:263-73.
4Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, De Stanchina E, et al. HER2 amplification: A potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2012;2:922-33.
5Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
6Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
7Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
8Giaccone G. EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer. Nat Clin Pract Oncol 2005;2:296-7.
9Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008;105:2070-5.
10Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Natl Acad Sci U S A 2005;102:7665-70.
11Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, et al. Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 2004;431:525-6.
12Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006;10:25-38.
13Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005;65:1642-6.
14Hirsch FR, Varella-Garcia M, Bunn PA Jr., Di Maria MV, Veve R, Bremmes RM, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-807.
15Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 2002;86:1449-56.
16Graveel CR, Tolbert D, Vande Woude GF. MET: A critical player in tumorigenesis and therapeutic target. Cold Spring Harb Perspect Biol 2013;5. pii: A009209.
17Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-50.
18Cappuzzo F, Janne PA, Skokan M, Finocchiaro G, Rossi E, Ligorio C, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 2009;20:298-304.
19Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009;27:1667-74.
20Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
21Beau-Faller M, Ruppert AM, Voegeli AC, Neuville A, Meyer N, Guerin E, et al. MET gene copy number in non-small cell lung cancer: Molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J Thorac Oncol 2008;3:331-9.
22Planchard D, Loriot Y, André F, Gobert A, Auger N, Lacroix L, et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol 2015;26:2073-8.
23Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19:2240-7.
24Ou SH, Agarwal N, Ali SM. High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression. Lung Cancer 2016;98:59-61.
25Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, et al. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett 2016;380:494-504.
26Cortinovis D, Abbate M, Bidoli P, Capici S, Canova S. Targeted therapies and immunotherapy in non-small-cell lung cancer. Ecancermedicalscience 2016;10:648.
27Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 2006;116:2695-706.
28Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
29Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, et al. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 2007;67:5779-88.
30Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009;69:3256-61.
31Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006;66:8163-71.
32Gallant JN, Sheehan JH, Shaver TM, Bailey M, Lipson D, Chandramohan R, et al. EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib. Cancer Discov 2015;5:1155-63.
33Chen J, Wang R, Zhang K, Chen LB. Long non-coding RNAs in non-small cell lung cancer as biomarkers and therapeutic targets. J Cell Mol Med 2014;18:2425-36.
34Sang H, Liu H, Xiong P, Zhu M. Long non-coding RNA functions in lung cancer. Tumour Biol 2015;36:4027-37.
35Cai B, Song XQ, Cai JP, Zhang S. HOTAIR: A cancer-related long non-coding RNA. Neoplasma 2014;61:379-91.
36Gutschner T, Hammerle M, Diederichs S. MALAT1 – A paradigm for long noncoding RNA function in cancer. J Mol Med (Berl) 2013;91:791-801.
37Yang Y, Li H, Hou S, Hu B, Liu J, Wang J. The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One 2013;8:e65309.
38Cheng N, Li X, Zhao C, Ren S, Chen X, Cai W, et al. Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer. Oncol Rep 2015;33:833-9.
39Pan H, Jiang T, Cheng N, Wang Q, Ren S, Li X, et al. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer. Oncotarget 2016;7:49948-60. [Doi: 10.18632/oncotarget. 10521].
40Cao M, Seike M, Soeno C, Mizutani H, Kitamura K, Minegishi Y, et al. MiR-23a regulates TGF-ß-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells. Int J Oncol 2012;41:869-75.
41Kitamura K, Seike M, Okano T, Matsuda K, Miyanaga A, Mizutani H, et al. MiR-134/487b/655 cluster regulates TGF-ß-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther 2014;13:444-53.
42Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2011;18:74-82.
43Shen H, Zhu F, Liu J, Xu T, Pei D, Wang R, et al. Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer. PLoS One 2014;9:e103305.
44Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005;65:9455-62.
45Shintani Y, Okimura A, Sato K, Nakagiri T, Kadota Y, Inoue M, et al. Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann Thorac Surg 2011;92:1794-804.
46Chang TH, Tsai MF, Su KY, Wu SG, Huang CP, Yu SL, et al. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med 2011;183:1071-9.
47Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010;141:69-80.
48Sato M, Shames DS, Hasegawa Y. Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis. Respirology 2012;17:1048-59.
49Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015;527:525-30.
50Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015;527:472-6.
51Buonato JM, Lazzara MJ. ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition. Cancer Res 2014;74:309-19.
52Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, et al. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. PLoS One 2013;8:e62104.
53Li L, Han R, Xiao H, Lin C, Wang Y, Liu H, et al. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res 2014;20:2714-26.
54Yu HG, Wei W, Xia LH, Han WL, Zhao P, Wu SJ, et al. FBW7 upregulation enhances cisplatin cytotoxicity in non-small cell lung cancer cells. Asian Pac J Cancer Prev 2013;14:6321-6.
55Cañadas I, Rojo F, Taus Á, Arpí O, Arumí-Uría M, Pijuan L, et al. Targeting epithelial-to-mesenchymal transition with met inhibitors reverts chemoresistance in small cell lung cancer. Clin Cancer Res 2014;20:938-50.
56Zakowski MF, Ladanyi M, Kris MG, Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 2006;355:213-5.
57Alam N, Gustafson KS, Ladanyi M, Zakowski MF, Kapoor A, Truskinovsky AM, et al. Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung. Clin Lung Cancer 2010;11:E1-4.
58Morinaga R, Okamoto I, Furuta K, Kawano Y, Sekijima M, Dote K, et al. Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer 2007;58:411-3.
59Tatematsu A, Shimizu J, Murakami Y, Horio Y, Nakamura S, Hida T, et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res 2008;14:6092-6.
60Tan CS, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol 2015;16:e447-59.
61Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014;4:1046-61.
62Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-11.
63Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462:1070-4.
64Jiang T, Zhou C. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer. Transl Lung Cancer Res 2014;3:370-2.
65Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015;372:1689-99.
66Song HN, Jung KS, Yoo KH, Cho J, Lee JY, Lim SH, et al. Acquired C797S mutation upon treatment with a t790m-specific third-generation EGFR Inhibitor (HM61713) in non-small cell lung cancer. J Thorac Oncol 2016;11:e45-7.
67Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 2015;21:560-2.
68Niederst MJ, Hu H, Mulvey HE, Lockerman EL, Garcia AR, Piotrowska Z, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res 2015;21:3924-33.
69Schildhaus HU, Schultheis AM, Ruschoff J, Binot E, Merkelbach-Bruse S, Fassunke J, et al. MET amplification status in therapy-naïve adeno and squamous cell carcinomas of the lung. Clin Cancer Res 2015;21:907-15.
70Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009;119:3000-10.
71Kankotia S, Stacpoole PW. Dichloroacetate and cancer: New home for an orphan drug? Biochim Biophys Acta 2014;1846:617-29.
72Garon EB, Christofk HR, Hosmer W, Britten CD, Bahng A, Crabtree MJ, et al. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. J Cancer Res Clin Oncol 2014;140:443-52.
73Olszewski U, Poulsen TT, Ulsperger E, Poulsen HS, Geissler K, Hamilton G.In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds. Clin Pharmacol 2010;2:177-83.
74Yang Z, Tam KY. Anti-cancer synergy of dichloroacetate and EGFR tyrosine kinase inhibitors in NSCLC cell lines. Eur J Pharmacol 2016;789:458-67.
75Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao T, et al. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation. Int J Oncol 2013;42:2094-102.
76Kelekar A, Thompson CB. Bcl-2-family proteins: The role of the BH3 domain in apoptosis. Trends Cell Biol 1998;8:324-30.
77Ni Chonghaile T, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene 2008;27 Suppl 1:S149-57.
78Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-81.
79Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Gossypol. A BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2008;112:1971-80.
80Meng Y, Tang W, Dai Y, Wu X, Liu M, Ji Q, et al. Natural BH3 mimetic (− )-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 2008;7:2192-202.
81Zhang M, Liu H, Guo R, Ling Y, Wu X, Li B, et al. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol 2003;66:93-103.
82Zhao R, Zhou S, Xia B, Zhang CY, Hai P, Zhe H, et al. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations. BMC Cancer 2016;16:491.
83Kang MH, Reynolds CP. Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009;15:1126-32.
84Cheng EH, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, et al. Conversion of Bcl-2 to a bax-like death effector by caspases. Science 1997;278:1966-8.
85Han B, Park D, Li R, Xie M, Owonikoko TK, Zhang G, et al. Small-molecule Bcl2 BH4 antagonist for lung cancer therapy. Cancer Cell 2015;27:852-63.
86Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013;3:1355-63.
87Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
88Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141-51.
89Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65:1089-96.
90Zago G, Muller M, van den Heuvel M, Baas P. New targeted treatments for non-small-cell lung cancer – Role of nivolumab. Biologics 2016;10:103-17.